| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |